Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) Short Interest Down 57.1% in May

Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) saw a large decrease in short interest during the month of May. As of May 29th, there was short interest totaling 57,741 shares, a decrease of 57.1% from the May 14th total of 134,469 shares. Based on an average trading volume of 40,907 shares, the short-interest ratio is presently 1.4 days. Currently, 0.5% of the company’s stock are sold short.

Hedge Funds Weigh In On Hong Kong Pharma Digital Technology

A hedge fund recently bought a new stake in Hong Kong Pharma Digital Technology stock. StoneX Group Inc. bought a new stake in Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 43,284 shares of the company’s stock, valued at approximately $36,000. StoneX Group Inc. owned approximately 0.39% of Hong Kong Pharma Digital Technology as of its most recent SEC filing.

Hong Kong Pharma Digital Technology Stock Down 7.6%

Shares of HKPD traded down $0.03 on Friday, reaching $0.42. The company’s stock had a trading volume of 66,181 shares, compared to its average volume of 738,006. The company has a current ratio of 2.93, a quick ratio of 2.73 and a debt-to-equity ratio of 0.28. Hong Kong Pharma Digital Technology has a twelve month low of $0.32 and a twelve month high of $2.58. The firm has a fifty day moving average of $0.58 and a 200-day moving average of $0.69.

Hong Kong Pharma Digital Technology (NASDAQ:HKPD) last posted its earnings results on Wednesday, March 18th. The company reported $0.01 earnings per share for the quarter. The business had revenue of $3.57 million during the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d)” rating on shares of Hong Kong Pharma Digital Technology in a report on Friday, May 1st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

About Hong Kong Pharma Digital Technology

Hong Kong Pharma is an exempted limited liability company formed under the laws of the Cayman Islands on August 17, 2023. As a holding company with no material operations of its own, Hong Kong Pharma conducts its operations through its wholly owned subsidiaries, Joint Cross Border Logistics Company Limited and V-Alliance Technology Supplies Limited, each a limited liability corporation incorporated in Hong Kong and collectively referred to as HK Subsidiaries. Our business offering consists of two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, primarily conducted through our Hong Kong subsidiary, Joint Cross Border, which we refer to as the “Supply Chain Services” division and (ii) OTC pharmaceutical cross-border procurement and distribution, primarily conducted through our Hong Kong subsidiary, V-Alliance, which we refer to as the “Procurement and Distribution” division.